ES2908854T3 - Método para producir un arenavirus antitumoral así como mutantes de arenavirus - Google Patents

Método para producir un arenavirus antitumoral así como mutantes de arenavirus Download PDF

Info

Publication number
ES2908854T3
ES2908854T3 ES19782905T ES19782905T ES2908854T3 ES 2908854 T3 ES2908854 T3 ES 2908854T3 ES 19782905 T ES19782905 T ES 19782905T ES 19782905 T ES19782905 T ES 19782905T ES 2908854 T3 ES2908854 T3 ES 2908854T3
Authority
ES
Spain
Prior art keywords
seq
mutant
carcinoma
nucleic acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19782905T
Other languages
English (en)
Spanish (es)
Inventor
Karl Lang
Cornelia Hardt
Michael Bergerhausen
Hilal Bhat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abalos Therapeutics GmbH
Original Assignee
Abalos Therapeutics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abalos Therapeutics GmbH filed Critical Abalos Therapeutics GmbH
Application granted granted Critical
Publication of ES2908854T3 publication Critical patent/ES2908854T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • C12N2760/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES19782905T 2018-09-12 2019-09-12 Método para producir un arenavirus antitumoral así como mutantes de arenavirus Active ES2908854T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102018215551.8A DE102018215551A1 (de) 2018-09-12 2018-09-12 Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
PCT/EP2019/074307 WO2020053324A1 (en) 2018-09-12 2019-09-12 Method for producing an antitumoral arenavirus as well as arenavirus mutants

Publications (1)

Publication Number Publication Date
ES2908854T3 true ES2908854T3 (es) 2022-05-04

Family

ID=68138008

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19782905T Active ES2908854T3 (es) 2018-09-12 2019-09-12 Método para producir un arenavirus antitumoral así como mutantes de arenavirus

Country Status (18)

Country Link
US (2) US12129281B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019533A1 (cg-RX-API-DMAC7.html)
JP (1) JP7583448B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210057782A (cg-RX-API-DMAC7.html)
CN (2) CN120158432A (cg-RX-API-DMAC7.html)
AU (1) AU2019340845B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021004451A2 (cg-RX-API-DMAC7.html)
CA (1) CA3111305A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000592A1 (cg-RX-API-DMAC7.html)
DE (1) DE102018215551A1 (cg-RX-API-DMAC7.html)
DK (1) DK3694868T3 (cg-RX-API-DMAC7.html)
ES (1) ES2908854T3 (cg-RX-API-DMAC7.html)
IL (1) IL281299B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002937A (cg-RX-API-DMAC7.html)
PH (1) PH12021550424A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101970UA (cg-RX-API-DMAC7.html)
WO (1) WO2020053324A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101833B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022180203A1 (en) 2021-02-26 2022-09-01 Abalos Therapeutics Gmbh New virus particles for therapeutic purposes
IL326615A (en) * 2023-08-31 2026-04-01 Abalos Therapeutics Gmbh Virus particles with improved entry into tumor cells
CN117867030A (zh) * 2024-01-15 2024-04-12 苏州健雄职业技术学院 小鼠肺癌细胞系cmt167荧光素酶稳转细胞株的构建与应用
CN122357626A (zh) * 2025-10-30 2026-07-10 山东第一医科大学(山东省医学科学院) 一种抑制塔姆德病毒感染的方法及tcp1抑制剂的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004034461B4 (de) 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
KR20110074563A (ko) 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
CN102439146A (zh) 2009-03-23 2012-05-02 巴斯德研究院 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物
WO2012093340A2 (en) * 2011-01-07 2012-07-12 Bioscience Slovakia Viral diagnostics
JP6162818B2 (ja) * 2012-12-12 2017-07-12 チルドレンズ ホスピタル オブ イースタン オンタリオ リサーチ インスティチュート インコーポレイテッド 脳癌の治療のための組成物及び方法
DE102015207036A1 (de) * 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
CN110167586B (zh) * 2016-11-04 2024-01-30 霍欧奇帕生物科技有限公司 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒

Also Published As

Publication number Publication date
MX2021002937A (es) 2021-07-16
ZA202101833B (en) 2022-10-26
SG11202101970UA (en) 2021-03-30
WO2020053324A1 (en) 2020-03-19
EP3694868A1 (en) 2020-08-19
US12129281B2 (en) 2024-10-29
DE102018215551A1 (de) 2020-03-12
JP7583448B2 (ja) 2024-11-14
EP3694868B1 (en) 2021-11-03
NZ774584A (en) 2024-09-27
IL281299B2 (en) 2025-07-01
CN112996802A (zh) 2021-06-18
CN120158432A (zh) 2025-06-17
IL281299B1 (en) 2025-03-01
US20250122244A1 (en) 2025-04-17
EP4019533A1 (en) 2022-06-29
CN112996802B (zh) 2025-03-11
CL2021000592A1 (es) 2021-09-10
KR20210057782A (ko) 2021-05-21
US20220033445A1 (en) 2022-02-03
JP2022500054A (ja) 2022-01-04
IL281299A (en) 2021-04-29
AU2019340845B2 (en) 2026-01-29
CA3111305A1 (en) 2020-03-19
BR112021004451A2 (pt) 2021-06-01
PH12021550424A1 (en) 2021-09-20
DK3694868T3 (da) 2022-02-07
AU2019340845A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
US20250122244A1 (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
ES2831080T3 (es) Virus oncolítico modificado
ES2905478T3 (es) Virus oncolíticos y moléculas terapéuticas
US12385067B2 (en) Compositions and therapeutic methods of microRNA gene delivery
EP3690034A1 (en) Isolated recombinant oncolytic poxvirus, pharmaceutical composition, and use thereof in treatment of tumors and/or cancer
TWI894357B (zh) 溶瘤病毒與經改造的免疫細胞聯合治療腫瘤
WO2018091680A1 (en) Cowpox-based oncolytic vectors
WO2020011754A1 (en) Chimeric vaccinia viruses
CN109568350B (zh) 一种用于治疗肿瘤的柯萨奇病毒
JP2013538572A (ja) 水疱性口内炎ウイルス
CN110387353A (zh) 一种用于治疗肿瘤的柯萨奇b组病毒
WO2018213412A1 (en) Recombinant oncolytic virus
RU2812046C2 (ru) Способ продуцирования аренавируса, а также мутантов аренавируса с противоопухолевыми свойствами
CN108495934B (zh) 将腺病毒和化学治疗剂组合用于治疗癌症
CN113583977B (zh) 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
HK40122461A (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
US20240318147A1 (en) Recombinant oncolytic virus, and construction method therefor and use thereof
HK40054624B (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
HK40054624A (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
Frendéus et al. Vector-based Cancer Immunotherapy
HK40056184B (en) Isolated recombinant oncolytic poxvirus capable of being regulated and controlled by microrna and use thereof